Enanta Pharma (ENTA) Tops Q3 EPS by 36c
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Join SI Premium – FREE
Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.07), $0.36 better than the analyst estimate of ($1.43). Revenue for the quarter came in at $18 million versus the consensus estimate of $17.44 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- UBS Upgrades Mitsubishi Heavy Industries Ltd (7011:JP) (MHVYF) to Buy
- Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
